In the News
Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease
Time to dive into the forefront of Alzheimer’s disease research! Join us for an exclusive on-demand webinar featuring Dr. Rudolf Tanzi, renowned expert and co-discoverer of all three early-onset familial Alzheimer’s disease genes, John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), and our CEO, Colin Hill.
Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer
The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins…
Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast
In this week’s episode of the Patients Rising podcast, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins…
Open to Debate: Is the FDA’s Caution Hazardous to your Health?
As the FDA tries to move safe and effective drugs as quickly as possible to patients who need them, it also needs to maintain the diligence and rigor necessary to prevent harms. Two experts look at the pace of FDA approvals and argue whether the agency is getting it right…
World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development
Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories…
Servier Doubles Up on Digital Twin Alliance with Aitia
French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.
Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect”…
UCB Enters Drug Discovery Collaboration with Aitia
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder…
Research Identifies Potential New Biomarkers of Atherosclerotic Coronary Artery Disease
This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data…
Becoming Aitia: Why GNS Shifted from AI Provider to Drug Discoverer
CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners…